NewsRoom Articles - Page 7 of 44

TuesdayMay 14, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada for DehydraTECH-GLP-1 Mode of Action Investigation

Lexaria, a global innovator in drug delivery platforms, just announced its newest relationship with the National Research Council of Canada (“NRC”) Specific molecular characteristics of the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, processed with Lexaria’s patented DehydraTECH(TM) technology, will be evaluated Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood compared to Rybelsus(R). This has potential for increased weight-loss and diabetic control Lexaria’s management is confident that this partnership will complement the company’s animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year Lexaria Bioscience (NASDAQ: LEXX), a…

ThursdayMay 09, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warrant Exercise and Issuance

Lexaria has entered an agreement wherein an existing accredited investor has exercised all their warrants to purchase shares The company has received $4.7 million from this undertaking, prior to deducting estimated offering expenses Proceeds fully fund Lexaria’s entire planned 2024 GLP-1 R&D program, leaving additional excess capital for general purposes Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its entry into a warrant exercise agreement with an existing accredited investor to exercise in full certain existing warrants initially issued in October 2023 and February 2024. The warrants will be exercised at $0.97 and $2.185 per…

TuesdayMay 07, 2024 8:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology

Lexaria, a global innovator in drug delivery platforms, through its patented DehydraTECH(TM) technology, looks to address the growing type 2 diabetes and obesity problem Given the success of previous studies, the company is looking to double down on glucagon-like peptide 1 (“GLP-1”) studies for 2024 GLP-1 treatments are a major player in managing weight and addressing diabetes, and Lexaria’s DehydraTECH(TM) drug delivery platform has the potential of replacing painful and expensive GLP-1 injections with an effective oral delivery path The company has already received independent ethics review board approval for its GLP-1 human pilot study #2, a milestone that brings…

TuesdayApr 30, 2024 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Reports 30% YOY Revenue Growth for Q1 2024; Projects $25-$30m Annual Revenue for 2024

Fr8Tech, a tech company on a mission to revolutionize cross-border shipping, just posted 30% year-over-year (“YOY”) revenue growth and a 278% YOY growth in Fr8Fleet volume for Q1 2024 This growth was attributed to the addition of the Fr8Fleet offering in 2022, which sought to address specific customer needs The company looks to build on this success by fostering even stronger relationships with existing customers and adding new customers to its network Its management believes that this approach will be integral in realizing its $25-$30 million annual revenue projection for the 2024 financial year Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech…

FridayApr 26, 2024 9:00 am

Turbo Energy S.A. (NASDAQ: TURB) Signs Distribution Agreement with El Corte Ingles

The European Union recently signed its inaugural ‘European Solar Charter’, aimed at driving the growth of the continent’s solar industry Turbo Energy has emerged as one of the leading companies within the European solar supply chain, with its array of residential and industrial energy storage solutions The company recently revealed that its range of ‘GoSolar’ residential solar energy solutions would be distributed by El Corte Ingles, Europe’s largest department store chain Turbo Energy also announced its FY2023 financial results, revealing FY23 revenues of USD 14.54 million The European Commission and representatives of the continent’s solar energy parts manufacturers came together…

ThursdayApr 25, 2024 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Grows Client Portfolio with Grupo Solave Cross-Border Logistics Contract

Fr8Tech, a tech company on a mission to revolutionize cross-border shipping, has announced its appointment as a logistics solutions provider for Grupo Solave, a leader in the Blue Agave market This increases a growing list of clients, including Amazon and Envases Universales, among others, adding to the company’s biggest year yet With the Tequila industry expected to grow by approximately 6% per annum, Fr8Tech expects to capitalize on this growth and support Solave with the logistic requirements that come with it Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping, under the USMCA agreement, by…

MondayApr 22, 2024 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval

Lexaria, a global innovator in drug delivery platforms, has received approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board GLP-1 drugs are utilized in the treatment of type 2 diabetes and obesity, a huge market, and are typically administered by painful and expensive injection, offering a major opportunity for Lexaria’s oral delivery platform This approval sets the company up for dosing within 30 days or less, with tentative study completion dates for this summer The study will comprise two study arms, the second study arm will investigate whether Lexaria’s patented DehydraTECH(TM)-enhanced semaglutide can effectively…

TuesdayApr 16, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Global Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies for 2024

Lexaria, a global innovator in drug delivery platforms, has added three new patents to its portfolio, bringing the total to 41 Two patents were awarded in the U.S., while the third was awarded in Japan, expiring in 2042 and 2041, respectively, if not extended Lexaria’s management plans to maintain focus on GLP-1 studies for 2024 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, in the month of April 2024, added three new patents to its portfolio. This brings the total number of awarded patents globally to 41, a testament to the versatility of its patented DehydraTECH(TM) technology…

FridayApr 12, 2024 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Offers Versatile and Reliable Cross-Border Logistics in the USMCA Region Amid Railroad Disruptions

Temporary railroad shutdowns in December 2023 stranded nearly 10,000 rail cars on both sides of the U.S. and Mexico border with embargoed goods on over 60 trains With disruptions to cross-border trade on the rise, companies are seeking more reliable ways to organize, facilitate, and monitor their cross-border shipments Fr8Tech, a tech company on a mission to revolutionize cross-border shipping, has positioned itself as the go-to brand for such services through its Fr8App system Fr8App seamlessly connects shippers with carriers and drivers, and offers comprehensive real-time tracking, fleet management, live pricing, and transportation management The ongoing migrant crisis has exposed…

ThursdayApr 11, 2024 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment

Lexaria, a global innovator in drug delivery platforms, has announced the appointment of Nelson Cabatuan, CPA, as its new CFO Nelson will lend over 15 years of experience in corporate finance and operations, having worked in key organizations within the industry, and will play an integral role in supporting upcoming GLP-1 human clinical studies and overseeing key financial areas of the company The appointment highlights Lexaria’s confidence in its recently confirmed focus on important GLP-1 studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the appointment of Nelson Cabatuan, CPA, as its new Chief Financial…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000